MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtho.2026.103894

Медицинская библиотека · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026

Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.

Hayashi Hidetoshi, Cho Byoung Chul, Spigel David R, Girard Nicolas, Lee Se-Hoon, Lu Shun, Popat Sanjay, Yang James Chih-Hsin, Passaro Antonio, Baldotto Clarissa, Gottfried Maya, Dias Josiane Mourão, Zimmer Gelatti Ana Caroline, Wang Bo, Kam Julian, Sethi Seema, Shah Sujay, Kamat Medha, Zhang Jiarui, Curtin Joshua C, William William N, Besse Benjamin

СтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION

Amivantamab plus lazertinib is approved for first-line management of EGFR-mutated advanced NSCLC. In MARIPOSA, amivantamab-lazertinib significantly improved overall survival versus osimertinib (hazard ratio [HR]: 0.75; p = 0.005). We evaluated acquired resistance mechanisms and their impact on second-line progression-free survival (PFS) in MARIPOSA.

METHODS

MARIPOSA (NCT04487080) assessed amivantamab-lazertinib versus osimertinib in previously untreated EGFR-mutated advanced NSCLC. Acquired resistance was assessed by Guardant360 next-generation sequencing of circulating tumor DNA from paired baseline and end-of-treatment plasma samples. Known resistance mechanisms included EGFR- orMET-dependent (e.g., C797S, MET amplification) and EGFR- or MET-independent (e.g., PIK3CA, RASorRAF, cell cycle, TP53orRB1 loss-of-function) resistance; absence of these detectable alterations constituted "Нет данных" resistance. Second-line PFS was defined as time from initiation of first subsequent therapy to investigator-assessed second progressive disease or death.

RESULTS

MET amplifications (3.4% versus 13.1%; nominal p = 0.002) and secondary EGFR mutations (1.4% versus 7.6%; nominal p = 0.01) were significantly reduced with amivantamab-lazertinib versus osimertinib, without significant increases in other known resistance pathways. Longer treatment with amivantamab was associated with fewer acquired MET and EGFR mutations. Median second-line PFS was substantially prolonged in the amivantamab-lazertinib versus osimertinib arm (8.4 versus 5.3 mo; HR: 0.72; nominal p = 0.02) among participants who started a first subsequent therapy. Participants harboring unknown resistance at end of treatment had longer median second-line PFS versus known resistance (7.4 versus 4.6 mo; HR: 0.63; nominal p = 0.01).

CONCLUSIONS

Amivantamab-lazertinib reduces common resistance mechanisms (e.g., EGFRorMET) versus osimertinib, suggesting that this regimen is changing the underlying biology of EGFR-mutant disease, contributing to both first- and second-line long-term efficacy outcomes.

Для цитирования: Hayashi Hidetoshi, Cho Byoung Chul, Spigel David R, Girard Nicolas, Lee Se-Hoon, Lu Shun, Popat Sanjay, Yang James Chih-Hsin, Passaro Antonio, Baldotto Clarissa, Gottfried Maya, Dias Josiane Mourão, Zimmer Gelatti Ana Caroline, Wang Bo, Kam Julian, Sethi Seema, Shah Sujay, Kamat Medha, Zhang Jiarui, Curtin Joshua C, William William N, Besse Benjamin. Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2026. DOI: 10.1016/j.jtho.2026.103894.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.